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Abstract
Background: Asthma surveys completed within the past 10 years in the Americas and the Asia-Pacific region have
shown significant underassessment of asthma severity in addition to undertreatment of asthma and have suggested
the need to improve long-term asthma management. In this study, we examined the frequency of asthma symptoms
and severe episodes, patients’ perceived asthma control, and use of asthma medications in Europe and Canada.
Methods: The Asthma Insight and Management survey (54 questions) was conducted in Europe (Germany, Italy, Spain
and the United Kingdom) and Canada from June 14 through July 28, 2010. Telephone interviews were conducted with
randomly screened patients or parents of adolescents (aged 12–17 years) with asthma; patients younger than 12 years
of age were excluded from the survey. Responses were reported separately for each country and in total for all five
countries.
Results: Seventy-five thousand three hundered thirty-five households were screened, and 2003 patients were
interviewed. The survey respondents represented a wide range of severity. Overall, 26 % of patients reported
symptoms daily or most days over the past 4 weeks, but most patients (81 %) perceived their asthma to be well or
completely controlled. Over the past year, 41 % of patients had episodes of frequent/severe symptoms, and 50 %
reported acute treatment (e.g. hospitalization, emergency visit, unscheduled physician visit) for asthma. Across
countries, 52 % of patients reported taking controller medication every day over the past year, 27 % reported not
taking any controller medication, and 14 % reported stopping controller treatment for 3 months or longer the last time
they stopped. Many patients considered asthma well controlled if each year they had only two urgent doctor visits
(50 %), three or four exacerbations (60 %), and/or one emergency room visit (41 %).
Discussion: This is the largest survey of patients with asthma in Europe and Canada in more than a decade.
Conclusion: In 2010, many surveyed patients in Europe and Canada reported features indicating uncontrolled asthma,
yet the majority believed they were well controlled, indicating that they had low expectations of long-term asthma
management. Use of controller medications was substantially less than recommended in treatment guidelines.
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Background
Asthma is a global public health problem affecting an esti-
mated 235 million people [1]. Poorly controlled asthma re-
sults in symptoms that are burdensome and that may
precede clinically significant exacerbations. The National
Review of Asthma Deaths (NRAD) reported that asthma
mortality in the United Kingdom was among the highest
in Europe and reviewed information on 195 patients who
died from asthma between February 2012 and January
2013 [2]. Only 23 % of these patients had been provided
personal asthma action plans to identify factors that trigger
or exacerbate asthma. The NRAD also found evidence that
reliever medication was overused and preventer medica-
tion was underused in the United Kingdom [2]. Patient
surveys reported in the previous two decades have indi-
cated an inadequate level of asthma control based on
symptoms, activity limitations and acute treatment (e.g.
hospitalization) [3–13]. The 1996 European Community
Respiratory Health Survey (ECRHS) found a high rate of
asthma attacks and asthma medication use among asth-
matic adults aged 20 to 44 years to be particularly high in
western Europe, the United Kingdom, Sweden, Australia,
New Zealand and the United States; this contrasts with
particularly low rates in Estonia, Greece and Spain [3]. A
survey using the same sampling strategy and instruments
as the ECRHS was conducted in 1993 to 1994 at six sites
across Canada, and it evaluated the sex-specific prevalence
of asthma attacks and asthma medication use. This survey
found the prevalence of asthma attacks and asthma medi-
cation use to be higher among women than men in all sites,
except for a higher rate of asthma attacks among men in
Vancouver [4]. The International Study of Asthma and
Allergies in Childhood (ISAAC; 1998) reported asthma-
symptom prevalence rates for 13- to 14-year-old children
in 56 countries that ranged from 1.6 % (Indonesia) to
36.8 % (UK) In addition, up to approximately 30 % of
Canadian children in the ISAAC survey reported asthma
symptoms over the past 12 months [5]. In the 1999
Asthma Insights and Reality in Europe (AIRE) study of
adults and children with asthma (N = 2803) in seven
European countries, only 5 % of patients met all of the
criteria for asthma control, and 7 % of patients had over-
night hospitalization in the previous year [6]. A later ana-
lysis of AIRE study data found overall that >50 % of
children and >40 % of adults with severe asthma perceived
their asthma to be well controlled and that disparities be-
tween patient perceptions and actual control were sub-
stantial although variable among the seven countries [7].
In a 1996 telephone survey of Canadian patients >16 years
of age with physician-diagnosed asthma (N = 829), 43 %
reported frequent or very frequent symptoms of asthma.
Furthermore, 26 % reported use of urgent care services in
the past year, and 21 % reported an asthma flare-up (i.e.
exacerbation) or need for urgent treatment within the past
6 months [14]. Additional survey results have corrobo-
rated a lack of control considered adequate at the time by
expert practitioners [10, 15].
The main goal of this Europe and Canada (EUCAN)
Asthma Insight and Management (AIM) survey was to
re-examine patient-reported beliefs concerning their
asthma and its management and to analyze whether
these beliefs have changed since previous surveys. In
particular, the purpose of the study was to explore and
document asthma-related patient perceptions, behaviors,
and presentation patterns. Another goal of this survey
was to gain a better understanding of the tools and tech-
niques physicians currently use to assess and manage
their patients’ asthma and to gauge the extent to which
physicians are following Global Initiative for Asthma
(GINA) guidelines [16] with regard to asthma assess-
ment and management techniques.
Methods
Study design
Patients
The EUCAN AIM survey was conducted in Germany,
Italy, Spain, the United Kingdom, France, and Canada
from June 14 through July 28, 2010. All questions were
originally drafted in English and translated to local lan-
guages. The translated questions were back-translated to
English and compared for meaning against the original
English version. Findings from France are not included
here owing to inaccurate translation of the questionnaire,
which was identified before completion of the survey in
France. Households were sampled by random-digit dialing
and systematically screened to determine whether there
were any household members with current physician-
diagnosed asthma, and if so, whether they (or their child)
had used any prescription medicine for control, preven-
tion, maintenance, or regular treatment of asthma in the
past year.
This survey was restricted to adults and adolescents
with current asthma, so households with no current pa-
tients with asthma or only patients younger than 12 years
with pediatric asthma screened out of the survey. Patient
consent was obtained before the interview began, and
the respondent could refuse to cooperate at any point in
the interview.
Outcomes
The survey was developed by the public opinion research
organization Abt SRBI, Inc. (New York, NY, USA) with in-
put from the steering committee and from prior published
AIM surveys. Telephone interviews lasting approximately
40 min were conducted with patients or parents of adoles-
cents (aged 12–17 years) with asthma. Interviewers with
survey organizations based in each target country read a
standard text to introduce the study and ask the survey
Sastre et al. World Allergy Organization Journal  (2016) 9:13 Page 2 of 12
questions. The data were not collected by doctors or other
health professionals.
All patients had physician-diagnosed asthma and used
asthma medication or had asthma symptoms in the past
year. The survey had 54 questions (Additional file 1),
and responses were reported separately for each country
as well as total estimates for all five countries.
Understanding of asthma exacerbations was explored
using several terms (asthma flare-ups, asthma exacerba-
tions, asthma attacks, and asthma worsening). The fre-
quency and duration of exacerbations or asthma worsening
was documented. Respondents were provided several sce-
narios of exacerbations and urgent doctor visits and asked
whether these indicated well-controlled asthma. Details of
asthma assessment and management by the patient and
their healthcare provider, use of oral corticosteroids, fre-
quency of use of a reliever inhaler, and use of controller
medications were ascertained.
Sample size and statistical analysis
The maximum margin of error for a sample size of 400
(individual country samples) is ±4.9 percentage points at
the 95 % confidence level. Descriptive comparison of re-
sponse rates among countries is provided, but no statis-
tical analysis of the results was performed.
Results
Demographic characteristic of patients
A total of 75,335 households were screened, and 2003 pa-
tients (400–403 per country) were interviewed (Tables 1, 2).
Data are not available for the number of qualified patients
with asthma who were not interviewed. The interviewed
patients were adults or parents of adolescents (age 12–17
years) with physician-diagnosed asthma who had, in the
previous year, taken asthma medication or had experienced
asthma symptoms. The proportion of females ranged from
64 % in the United Kingdom to 69 % in Italy, overall mean
66 %. The mean age of respondents ranged from 42 years
in Germany to 51 years in the United Kingdom, overall
mean 47 years. The respondents’ mean age at diagnosis of
asthma was 25 years, with the mean age at asthma diag-
nosis ranging from 22 years in Canada to 27 years in
Germany (Tables 1, 2).
Main results
On average, patients reported that they had symptoms for
3 years before their asthma diagnosis, although subjects
answering the questionnaire represented a wide range of
severity. Overall, more than one in four patients reported
symptoms every day or most days over the past 4 weeks.
In addition, 11 % of patients reported symptoms every
night or most nights over the past 4 weeks, and 21 % of
patients reported symptoms during exercise, play, or
physical exertion every day or most days over the
past 4 weeks (Fig. 1). While more than 25 % of pa-
tients reported that daytime symptoms occurred every
day or most days, indicating moderate or severe per-
sistent asthma, over half (56 %) of patients reported
that daytime symptoms occurred less than once a
week, which indicates they had mild or intermittent
asthma. The majority of patients (61 %) reported
allergens (ie., dust, pollen, grass, animals, and insects)
to be the most common factor to trigger their asthma
or make their symptoms worse. In addition, 31 % of
patients reported environmental factors (i. e., pollu-
tion, chemicals, fumes, tobacco smoke, and perfume)
and 28 % reported weather changes as asthma triggers.
Other asthma triggers reported less frequently were
exercise (21 %), emotional factors (11 %) and viruses/colds
(11 %).
Despite the relatively high proportion of asthma patients
reporting daytime symptoms, nighttime symptoms, and
symptoms during exercise or exertion on every day or
most days during the past 4 weeks, 81 % of patients per-
ceived their asthma to be well or completely controlled
over this period (Fig. 2). Using objective criteria based on
GINA guidelines, asthma control in the past 4 weeks was
worse than the perceived asthma control reported by
patients. Only 18 % would be classified as having con-
trolled asthma according to the GINA guidelines, while
58 % would be classified as partially controlled, and 24 %
as uncontrolled.
Asthma burden
Overall, nearly half of adults and adolescents with asthma
in Europe and Canada reported that asthma symptoms are
extremely or moderately bothersome when they have them.
Furthermore, approximately two of five survey respondents
reported episodes when asthma symptoms were more fre-
quent or more severe than normal in the past 12 months.
However, there was substantial variation across countries in
the proportion of asthma sufferers who reported these
episodes of symptom worsening (more frequent or more
severe) in the past 12 months. The proportion of patients
reporting symptom-worsening episodes in the past
12 months ranged from 28 to 61 % (Fig. 3).
Overall, patients with asthma in Europe and Canada re-
ported a median of three asthma exacerbations in the past
Table 1 Study design
Population Sampling frame Interview
length
Adults and parents of adolescents
(age 12–17 years) with asthma
(physician diagnosed and past year
medication or asthma symptoms)
Telephone screening
of national random
digit dialing sample
of households
Mean:
37.9 min
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12 months. The mean duration of these episodes was
12 days: 8 days in Canada, 11 days in the UK, 13 days in
Germany, 14 days in Spain, and 15 days in Italy. The me-
dian duration of these episodes was 3 days in all countries
except Spain, where the median duration was 5 days. It is
likely that exacerbations of long duration occurred among
many patients in each country to push the means so far
above the medians. Although the particular pattern of
acute care for asthma varies among countries depending
on their healthcare system, half of the adults and adoles-
cents with asthma in Europe and Canada reported acute
treatment (e.g. hospitalization, emergency visit, un-
scheduled physician visit) for asthma in the past year
(Fig. 4). A substantial portion of the asthma patient
population experience what it perceives as life-
threatening asthma episodes. Asthma exacerbations
are physically threatening and emotionally significant
for patients. One-third or more of all adults and ado-
lescents with asthma reported having had an asthma
episode so bad they thought their lives were in
danger (Table 3). The survey questions did not allow
discernment of the severity of exacerbations among
the respondents. However, it can be presumed that
up to 51 % of patients, who reported acute treatment
for asthma in the past year, had severe exacerbations.
In addition to the reported occurrence of frequent/
severe asthma episodes and exacerbations, the EUCAN
AIM survey demonstrates the significant impact of
asthma on patients’ day-to-day lives. Overall, 19 % of
adults and adolescents reported that their asthma
caused them to miss work or school in the past year,
with a median of 7 days missed (Table 3), 31 % of
patients reported that they had episodes of sufficient
severity to be short of breath while sitting still, 23 %
reported that they had severe episodes limiting their
speech to only a few words at a time, and 28 % reported
that they had been awakened frequently at night by
asthma symptoms.
Asthma treatment
More than half of patients reported that they had taken
prescription controller medicines for their asthma in
the past 4 weeks. The proportion of patients with
asthma using prescription controller medicines in the
past 4 weeks was 49 % in Italy, 58 % in the United King-
dom, 59 % in Canada, 60 % in Spain, and 61 % in
Germany.
Use of controller medications reported in the EUCAN
AIM survey shows disagreement between guideline rec-
ommendations for daily use and patient choices. Overall,
Table 2 Study design
Country Households screened, n Asthmatics interviewed, n Female, % Mean age, years Mean age at Diagnosis, years
Canada 7405 401 67 45 22
Germany 22,293 402 67 42 27
Italy 13,620 400 69 50 25
Spain 24,404 400 65 44 25
United Kingdom 7613 400 64 51 25
TOTAL 75,335 2003 66 47 25
Fig. 1 Patient-reported frequency of symptoms in the past 4 weeks (every day or most days)
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more than half of patients reported taking controller
medication every day over the past year. However, ap-
proximately one-quarter of subjects reported not taking
any controller medication in the past year (Fig. 5).
Correlations between usage of medication and reported
asthma control indicate that some patients who re-
ported infrequent symptoms also reported use of daily
controller therapy (Table 4), a treatment that patients
with more severe asthma would require. Among
patients who used prescription controller medication at
any time during the past year, up to 12 % of patients
reported stopping controller treatment for at least 1 to
2 weeks the last time they stopped (Fig. 6).
Nearly seven of 10 patients with asthma in Europe
and Canada reported that they had taken prescription
quick-relief or rescue medicines for their asthma in the
past 4 weeks (Table 3). This means that about 30 % had
not used an inhaler in the last 4 weeks, emphasizing
that many had mild or intermittent disease where one
would not expect regular controller treatment to be
mandatory. Forty-six percent of all subjects (range 34 %
in Italy to 56 % in UK) had used an inhaler for quick re-
lief of asthma symptoms at least once a week over the
last year, indicating the presence of persistent asthma.
Among patients who reported having symptoms every
day, 23 % did not use rescue medications in the past
year, although 66 % of these patients used controller
medication every day (Table 4). Overall, however, at
least 19 % of patients with daily symptoms had not used
any inhaled medication in the past year. The propor-
tion of EUCAN AIM respondents who reported taking
an oral steroid (pill or liquid) to manage their asthma
symptoms in the past 12 months ranged from 21 % in
the United Kingdom to 50 % in Italy. On average,
patients took oral steroids for 3 days or longer twice in
the past year (Table 3).
In a further analysis, 19 % of patients who experi-
enced symptoms every day did not take a controller
medicine in the past year, and 11 % took it less than
once a week. In contrast, among patients who
Fig. 3 Proportion of patients reporting episodes in the past 12 months when asthma symptoms were more frequent or more severe
than normal
Fig. 2 Proportion of patients who perceived their asthma as completely or well controlled in the past 4 weeks
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Fig. 4 Proportion of patients reporting acute treatment for asthma in the past year
Table 3 EUCAN AIM survey responses
Survey questions EUCAN Canada Germany Italy Spain UK
(N = 2003) (n = 401) (n = 402) (n = 400) (n = 400) (n = 400)
Control classification based on 2009 GINA, %
▪ Well controlled 18 16 10 17 12 24
▪ Partly controlled 58 59 66 64 64 51
▪ Uncontrolled 24 25 24 20 24 25
Had episodes in the past 12 months when asthma symptoms
were more frequent or more severe than normal, %
38 61 52 40 37 28
▪ Median number of episodes, n 3 3 6 3 2 3
Have ever had an asthma episode perceived as life threatening, % 33 40 39 32 44 27
Have in the past year had an asthma episode perceived as life threatening, % 9 10 14 10 13 5
Missed work or school in the past year due to asthma, % 19 21 24 16 23 12
▪ Median number of days missed, n 7 6 10 10 5 4
Used quick relief medication for asthma in past 4 weeks, % 68 69 59 66 71 80
Used inhaler for quick relief of asthma symptoms at least once a week
over the past year, %
46 43 35 34 49 56
Used an oral steroid (pill or liquid) to manage asthma symptoms in the
past year, %
32 30 41 50 39 21
▪ Median number of times an oral steroid was used for 3 days or longer
in the past year, n
2 3 2 3 2 2
How the doctor usually assesses asthma, %
▪ Has the patient fill out a questionnaire 7 7 13 2 6 6
▪ Gives the patient a breathing test or spirometry 47 24 54 25 59 50
Has a doctor-developed written action plan for asthma treatment, % 23 18 25 39 45 15
Agree with the following statements, %
▪ Maintenance medicines should be taken every day 66 64 65 57 64 69
▪ Maintenance medicines are not necessary when asthma symptoms are not
experienced regularly
48 59 60 48 59 39
▪ Rescue medicines can be used every day if needed 67 75 58 59 62 75
▪ Fear of asthma exacerbations keeps me from doing the things I want to 26 25 32 35 36 18
▪ I worry about using oral steroids, like prednisone 34 54 32 30 40 34
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experienced symptoms less frequently than once a
week, 33 % did not take any controller medication in
the past year (Table 4).
Attitudes about asthma
Patients with asthma in EUCAN had low expectations
of disease management. At least half of patients con-
sidered their asthma well managed if their asthma
bothers them less than half the time when they exer-
cise, well managed if they only have two urgent care
visits for asthma per year, and well controlled if they
have only three or four exacerbations a year (Fig. 7). In
Europe and Canada, more than one in four patients
with asthma agree that fear of asthma exacerbations
keeps them from doing the things that they want to do
(Table 3). About one-third of asthma patients in the
European countries also agree that they worry about using
oral steroids. Concerns about the use of oral steroids are
much higher in Canada, where more than half of asthma
patients worry about using oral steroids.
When survey respondents were asked how their doctor
usually assesses asthma, 2 to 13 % of asthma patients
Fig. 5 Patient-reported frequency of asthma controller medicine use in the past year
Table 4 Daytime symptom frequency and use of rescue and controller medication among EUCAN patients
Frequency of
daytime symptoms
Frequency of rescue medication use, n (%)a Frequency of controller medication use, n (%)a
Every day 3–6/week 1–2/week <1/week Not used in past year Every day 1–6 / week <1/week Not used in past year
Every day 159 (52) 23 (8) 18 (6) 33 (11) 70 (23) 199 (66) 12 (4) 32 (11) 59 (19)
(n = 303,a 288b)
Most days 106 (47) 24 (10) 15 (7) 35 (15) 48 (21) 149 (66) 18 (8) 30 (13) 31 (13)
(n = 226,a 213b)
Twice/week 66 (27) 26 (11) 30 (12) 44 (18) 74 (31) 116 (49) 31 (13) 40 (17) 52 (22)
(n = 240,a 248b)
Once/week 32 (24) 11 (8) 16 (12) 35 (26) 38 (29) 62 (47) 10 (7) 26 (20) 35 (26)
(n = 132,a 133b)
Less than once/week 272 (23) 57 (5) 93 (8) 332 (29) 407 (35) 507 (44) 58 (5) 210 (18) 386 (33)
(n = 1162,a 1120b)
Total 635 (31) 140 (7) 171 (8) 478 (23) 638 (31) 1033 (50) 129 (6) 337 (16) 562 (27)
(n = 2063,a 2002b)
aSample sizes and proportions weighted by the size of the population and the prevalence of asthma in each of the countries
bUnweighted sample sizes
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reported that their doctor had them fill out a question-
naire. About one-quarter of patients with asthma in
Canada and Italy, as well as at least half of asthma pa-
tients in the United Kingdom, Germany, and Spain said
that their doctor usually assessed their asthma with a
breathing test or spirometry. Many patients may have
simply had peak flow monitoring rather than full spir-
ometry. The proportion of patients reporting that they
had a doctor-developed written action plan for asthma
treatment was one-quarter or less in Germany, Canada,
and the United Kingdom, in contrast to over one-third
in Italy and Spain.
Overall, two-thirds of patients with asthma agreed
that maintenance medicines should be taken every
day. However, more than half of patients in Spain,
Canada, and Germany also agree that maintenance
Fig. 6 Proportion of patients who stopped taking asthma controller medicine in the past year (as percentage of those taking controller medicine
at any time of the year)
Fig. 7 Patient-reported attitudes about asthma management and control
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medicines are not necessary when asthma symptoms
are not experienced regularly. Another negative find-
ing is that two-thirds of patients with asthma agreed
with the statement that rescue medicines can be used
every day if needed. Moreover, about one-third of
patients with asthma in the European countries re-
ported that they worry about using oral steroids.
Patients’ attitudes and beliefs about treatment are im-
portant because they may affect asthma management
and control.
Discussion
The EUCAN AIM is the largest survey of patients with
asthma in Europe and Canada in more than a decade.
The survey was conducted by telephone interview (me-
dian time, 39.7 min) in 2420 adults or parents/guardians
of adolescents (aged 12–17 years) with current diag-
nosed asthma. Based on national probability samples of
approximately 400 persons aged 12 years and older
with current asthma, the study showed significant un-
met needs in asthma care in Europe and Canada, with
persistence of significant asthma symptoms and exacer-
bations, low expectations, and marked undertreatment.
Up to 19 % of those taking controller medication
reported gaps in treatment of 3 months or longer. The
study is limited, however, in that between-country re-
sults were not analyzed statistically and self-selection
bias may preclude the generalizability of study findings
to the general population. Another study limitation is
that thorough data on correlations between asthma
severity and medication usage were not obtained in the
survey. About half of patients were very infrequent
users of reliever treatment, which means almost
certainly that they had mild or intermittent disease and
were unlikely to be prescribed maintenance medica-
tion. The finding of low reliever use among some
patients suggests they had very mild disease or were
among those who reported using controller medica-
tions every day and so did not feel the need for rescue
medication. However, nearly one in four patients
reported that they used rescue medication every day
but had daytime symptoms less than once a week.
Given that assessment of asthma severity determines
the medications that are required, it is not reasonable
to anticipate that patients with different degrees of
asthma severity would require the same controller or
rescue therapy.
Patients in this survey experienced relatively frequent
asthma symptoms and approximately 40 % reported
symptoms to be moderately to extremely bothersome.
Some patients with troublesome asthma who reported fre-
quent bronchodilator use were not prescribed controller
therapy. Findings from the National Review of Asthma
Deaths (NRAD) indicate that 14 % (n = 27) patients who
died from asthma in the United Kingdom were prescribed
a single-component quick-relief medication around the
time of death. At least 3 % (n = 5) patients were on reliever
monotherapy without controller treatment [2]. In
EUCAN AIM, nearly half of patients who reported epi-
sodes of symptom worsening also reported that they
needed hospitalization, emergency room care, or other
unscheduled medical visits for asthma episodes or
exacerbations over the past year. Over the past year,
nearly one-third of patients had required a course of
oral steroids, and nearly 10 % of patients reported
having an episode as being sufficiently grave that they
felt their life was in danger.
While our findings showed similarities across coun-
tries in patient-perceived level of asthma control, they
also revealed that asthma is far from being well con-
trolled. Our survey revealed a huge discrepancy between
the proportion of asthma patients agreeing with the
statement that their asthma is well or completely con-
trolled (80 %) and the proportion who would be classi-
fied as having controlled asthma according to GINA
guidelines (18 %) [16]. The patients with asthma who
were surveyed had low expectations about what
constitutes well-controlled asthma given their reported
symptom frequency, exacerbations, use of quick-relief
medicine, and emergency room visits or other urgent
care. This indicates that patients are satisfied with what
clinicians consider to be an unacceptable burden of
disease.
The untoward consequences of uncontrolled asthma
and its impact on costs and exacerbation risk have been
reported in several epidemiologic studies [17–19]. In
addition, the burden of asthma identified in previous
surveys of the region [4, 6–8, 14] continues to exist,
even though effective controller medications are
available and treatment guidelines have been widely
disseminated.
Patient-reported activity limitations, missed school/
work days, number of emergency visits, and number
of hospitalizations in the present survey suggest a
lack of improvements in asthma control in Europe
and Canada over the past decade, and reveal signifi-
cant unmet needs with regard to the current state of
asthma care in these countries. Although most sur-
vey respondents recognized that maintenance medi-
cation for asthma should be used every day, many
reported that they did not take prescription controller
medicines daily. Other patients discontinued controller
medicines altogether for a week or longer in the past year,
and still other asthma patients had not taken asthma
maintenance medicines in the past year. These findings
are consistent with parallel AIM surveys conducted in the
United States [20, 21], the Asia-Pacific region [22], and
Latin America [23].
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Similarities and differences exist between EUCAN
and US AIM survey results (Table 5). In addition, the
1999 AIRE study, which surveyed 2803 patients with
asthma in France, Germany, Italy, the Netherlands,
Spain, Sweden, and the United Kingdom found that
38 % of children and 50 % of adults had daytime
symptoms at least once a week. The EUCAN AIM
survey finding that 26 % of patients reported daytime
symptoms every day or most days suggests that pa-
tients’ control of their asthma symptoms has not im-
proved in the past decade despite published guidelines
and availability of effective controller treatments.
Furthermore, the AIRE and EUCAN AIM surveys
showed similar discrepancies between patient-reported
asthma control and control levels based on GINA
guidelines.
The reporting of regular, as needed quick-relief inhaler
use by two-thirds of patients in the EUCAN AIM survey
is consistent with the findings of a survey involving 1022
patients with asthma in five European countries, in
which 64 % of patients reported that treatment with
immediate results (ie, quick relief ) gave them a reason
for regular use of that treatment [24].
Conclusions
In 2010, many patients in Europe and Canada had low
expectations of long-term asthma management and
unacceptable levels of asthma control, despite the
availability of effective medications. Furthermore, their
reported use of controller medications did not reflect
guideline recommendations for uninterrupted daily use.
Although more than half of those surveyed reporting
taking controller medication every day, discontinuation
of this medication was common. The survey findings
yield a number of important insights about asthma and
the current state of asthma management. Many patients
believe that their symptoms are well controlled, despite
reporting substantial symptoms and morbidity. Patients
with asthma have very low expectations for controlling
their disease, with 60 % considering their asthma to be
well controlled if they have only three or four exacerba-
tions a year.
Patient acceptance of asthma burden, as well as the
apparent lack of conviction on treatment recommenda-
tions and goals, are persistent problems which need to
be addressed by improved implementation of asthma
guidelines and patient education.
Table 5 Similarities and differences between EUCAN and US AIM survey results
Proportions of patients (%)
Patient reports EUCAN AIM US AIM [20, 21]
Had well-controlled asthma based on guidelines 18a 29
Had severe asthma episodes in the past year 38b 52
Ever had an asthma exacerbation perceived as life-threatening 33 36
Missed work or school in the past year due to asthma 19 22
Had overnight hospitalization for asthma in the past year 7 6
Agreed with the statement that:
• maintenance medication should be taken every day 66 74
• maintenance medication is not necessary when asthma symptoms are not
experienced regularly
48c 40
• rescue medication can be used every day if neededd 67 67
Used prescribed controller medication in the past 4 weeks 57 70
Used quick-relief inhaled medication at least once a week over the past year 43 51
Used an oral steroid (pill or liquid) to manage asthma symptoms in the past year 32 35
Worry about using oral steroids, like prednisone 34e ≥52f
Had a doctor-developed written action plan for asthma treatment 23g 32h
Some of the country-specific EUCAN results were similar to the US results
ain the United Kingdom, 25 % of patients reported that they had well-controlled asthma
bin Germany, 52 % of patients reported that they had severe asthma episodes over the past year, with a median of 6 severe episodes during the year (the median
was 3 in all other countries, including the US)
cin the United Kingdom, 39 % of patients agreed with the statement that maintenance medication is not necessary when asthma symptoms are not experienced
regularly; this finding reveals misalignment of patient beliefs and asthma management guidelines
dpatients who need to use rescue medication every day are likely to have poorly controlled or severe asthma
ein Canada, 54 % of patients reported that they worry about using oral steroids
fpatients’ concern about oral steroid use was stratified by their level of asthma control (well controlled [52 %], not well controlled [56 %], or very poorly
controlled [61 %])
gin Italy and Spain, 39 and 45 % of patients, respectively, reported that they had a doctor-developed written action plan for asthma
honly 25 % of US patients had ever completed the Asthma Control Test [25]
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